Care Robotics: Vendors, Adoption, and Outcomes Evidence 2026 | Policy & Market Intelligence

Description

List of Tables

Japan has spent two decades and substantial public money trying to robotize elder care, and the experiment is now producing its first real verdicts. The policy logic is unavoidable: the care sector faces a workforce shortfall projected in the hundreds of thousands by 2040, wages are constrained by the LTCI fee system, and provider bankruptcies are rising. Robotics and monitoring technology are the state's chosen partial answer, supported by subsidy programs from METI and MHLW that have seeded transfer-assist exoskeletons, mobility aids, monitoring sensors, and communication robots across thousands of facilities. What two decades of subsidization have not settled is whether the technology pays its way outside the subsidy window.

The evidence question is now the commercial question. Adoption surveys show persistent gaps between trial deployment and sustained use, with facilities citing setup burden, staff turnover, and mismatch with care routines. Outcomes evidence varies sharply by category: CYBERDYNE's HAL carries a neuroplasticity-based rehabilitation evidence program unlike anything else in the field; lift-assist devices from INNOPHYS and JTEKT target caregiver injury rather than patient outcomes; monitoring systems from Fujitsu and Exawizards promise documentation and night-shift relief with different evidence structures. Meanwhile the vendor landscape is sorting itself, with Exawizards reaching its first operating profit as a software-model marker, and international entrants from Ekso Bionics to Fourier Intelligence and Wandercraft testing whether Japanese care robotics is an export-grade category.

This report maps vendors, adoption, and evidence as one system. It profiles the Japanese incumbents, CYBERDYNE, INNOPHYS, JTEKT, Panasonic, Toyota, Fujitsu, Exawizards, and SoftBank Robotics, and the international participants, Ekso Bionics, Ottobock, Fourier, Wandercraft, Arjo, PAL Robotics, and Etac/Molift, category by category: rehabilitation robotics, lift-assist and transfer devices, monitoring and sensors, documentation AI, and communication robots. It reconstructs the subsidy architecture and its eligibility rules, analyzes facility-level adoption economics under LTCI fee constraints, reviews the outcomes-evidence base category by category, and benchmarks Japan against US, EU5, and Chinese care-technology markets.

The report serves robot and device makers planning product and evidence strategy, care operators evaluating capital and workflow investment, policymakers reviewing subsidy design, and private-equity and strategic investors assessing a category where public money, labor scarcity, and uneven evidence intersect. Each category chapter ends with the conditions under which adoption converts from subsidized trial to routine operation.

Scope and Coverage

The report covers care-robotics and monitoring technology in Japan across rehabilitation, transfer-assist, monitoring, documentation, and communication categories, including subsidy mechanics, facility economics, outcomes-evidence structure, and vendor strategy, with international comparison across the US, EU5, and China. Industrial and medical-surgical robotics are outside scope.

Report Highlights

Category-by-category vendor landscape with Japanese incumbents and international entrants
Subsidy architecture: METI and MHLW programs, eligibility, and award mechanics
Facility adoption economics under LTCI fee constraints
Outcomes-evidence review by category, from HAL's rehabilitation program to monitoring systems
Workforce-shortfall context and its implications for technology demand
International comparison of care-technology markets and export prospects

Product Code: JPH-019

Table of Content

1. Executive Summary

2. Care Robotics: Policy and Institutional Framework

3. Reimbursement, Pricing, and Funding Flows

4. Provider and Operator Landscape: Structure and Economics

5. Workforce and Capacity Analysis

6. Technology and Vendor Ecosystem

7. International Comparison: US, EU5, and China

8. Implications for Entrants and Investors

9. Appendix: Methodology and Sources

Companies Mentioned

CYBERDYNE (JP) - HAL exoskeleton with a neuroplasticity evidence program
INNOPHYS (JP) - Muscle Suit lift-assist devices
JTEKT (JP) - J-PAS lift-assist exoskeletons
Fujitsu (JP) - mmWave privacy-preserving monitoring sensors
Exawizards (JP) - AI care software for documentation and monitoring
Panasonic (JP) - care robotics and monitoring products
Toyota (JP) - HSR and mobility-assist robotics programs
Ekso Bionics (US) - rehabilitation exoskeletons
Ottobock (DE) - orthopedic robotics and exoskeleton components
Fourier Intelligence (CN) - RehabHub and ExoMotus rehabilitation robotics
Wandercraft (FR) - Atalante self-balancing exoskeleton
Arjo (SE) - patient-handling and lift equipment for care homes
PAL Robotics (ES) - assistive and social robots
SoftBank Robotics (JP) - service robots deployed in care settings
Etac/Molift (NO) - transfer-assist devices

Product Code: JPH-019

List of Tables

Table 1. Care robotics taxonomy: rehabilitation, transfer-assist, monitoring, documentation, and communication categories
Table 2. Policy context: workforce-shortfall projections and the care-labor framework to 2040
Table 3. Technology-readiness framework for care-robotics evaluation
Table 4. Milestones in Japanese care-robotics policy and development by year
Table 5. Care-facility population: operator types, sizes, and technology-relevant structures
Table 6. Caregiver task-burden framework: transfer, mobility, documentation, and night-shift loads
Table 7. Care-recipient population structure relevant to robotics applications
Table 8. Facility staffing models and their interaction with technology adoption
Table 9. Regional and prefectural variation in care-robotics deployment
Table 10. METI care-robot development and demonstration programs: structure and history
Table 11. MHLW and AMED funding streams for care technology
Table 12. Prefectural and municipal subsidy programs for facility adoption
Table 13. Subsidy lifecycle: application, award, and reporting mechanics
Table 14. Eligibility rules and their effect on vendor product strategy
Table 15. CYBERDYNE HAL: exoskeleton systems and the neuroplasticity evidence program
Table 16. INNOPHYS Muscle Suit: lift-assist device line and deployment model
Table 17. JTEKT J-PAS: lift-assist exoskeleton positioning
Table 18. Panasonic care-robotics and monitoring product programs
Table 19. Toyota HSR and mobility-assist robotics programs
Table 20. Fujitsu mmWave privacy-preserving monitoring sensors
Table 21. Exawizards AI care software: documentation and monitoring products
Table 22. SoftBank Robotics service robots in care settings
Table 23. Arjo and Etac/Molift: patient-handling and transfer-assist equipment
Table 24. Ekso Bionics and Ottobock: rehabilitation-exoskeleton positions
Table 25. Fourier Intelligence RehabHub and ExoMotus: China-origin rehabilitation robotics
Table 26. Wandercraft Atalante and PAL Robotics: European entrant profiles
Table 27. Product-regulation structure for care robots in Japan
Table 28. Medical-device versus non-medical classification boundary for rehabilitation robotics
Table 29. FDA and EU MDR pathways for rehabilitation and assistive robotics
Table 30. China regulatory and industrial-policy context for care robotics
Table 31. Safety-standards and certification frameworks for care robots
Table 32. LTCI fee structure and its interaction with technology investment
Table 33. Facility capital-budget frameworks for robotics acquisition
Table 34. Leasing, rental, and subscription models for care technology
Table 35. LTCI add-on and incentive structures relevant to technology use
Table 36. US and EU5 funding and payment comparison for care technology
Table 37. Outcomes-evidence framework: what each category must demonstrate
Table 38. Rehabilitation-robotics evidence base: study structures under review
Table 39. Transfer-assist evidence base: caregiver-injury and workflow study structures
Table 40. Monitoring-system evidence base: falls, documentation, and night-shift study structures
Table 41. Communication-robot evidence base and its limitations
Table 42. Adoption-survey landscape: trial-to-sustained-use conversion structure
Table 43. Unmet needs: setup burden, staff turnover, and routine mismatch
Table 44. Evidence-generation program designs for vendors
Table 45. Facility business-case framework for robotics investment
Table 46. Operator technology-adoption archetypes
Table 47. Export and internationalization pathways for Japanese care robotics
Table 48. Policy agenda: subsidy redesign, LTCI incentives, and evidence requirements
Table 49. Report methodology: vendor audit, subsidy-document analysis, and interview base
Table 50. Glossary of robotics, subsidy, and care-system terms

List of Figures

Figure 1. Care-robotics category map
Figure 2. Workforce-shortfall framework diagram to 2040
Figure 3. Technology-readiness evaluation framework
Figure 4. Japanese care-robotics policy timeline
Figure 5. Care-facility operator structure map
Figure 6. Caregiver task-burden schematic
Figure 7. Care-recipient population framework
Figure 8. Staffing-model interaction with technology adoption
Figure 9. Regional deployment variation framework
Figure 10. METI program structure and history diagram
Figure 11. MHLW and AMED funding-stream map
Figure 12. Prefectural subsidy program landscape
Figure 13. Subsidy lifecycle flow
Figure 14. Eligibility-rule influence on product strategy
Figure 15. HAL system architecture and evidence-program map
Figure 16. Muscle Suit product line and deployment model
Figure 17. J-PAS positioning diagram
Figure 18. Panasonic care-robotics program map
Figure 19. Toyota HSR program structure
Figure 20. Fujitsu mmWave monitoring architecture
Figure 21. Exawizards product structure diagram
Figure 22. SoftBank Robotics deployment map in care settings
Figure 23. Arjo and Etac/Molift transfer-equipment landscape
Figure 24. Ekso and Ottobock rehabilitation-exoskeleton positions
Figure 25. Fourier Intelligence product-line map
Figure 26. Wandercraft and PAL Robotics entrant profiles
Figure 27. Product-regulation structure in Japan
Figure 28. Medical-device classification boundary diagram
Figure 29. FDA and EU MDR pathway comparison
Figure 30. China regulatory and industrial-policy map
Figure 31. Safety-standards and certification framework
Figure 32. LTCI fee interaction with technology investment
Figure 33. Facility capital-budget framework diagram
Figure 34. Leasing and subscription model map
Figure 35. LTCI add-on and incentive structure diagram
Figure 36. US and EU5 funding comparison map
Figure 37. Outcomes-evidence requirement framework by category
Figure 38. Rehabilitation-robotics evidence-map structure
Figure 39. Transfer-assist evidence-map structure
Figure 40. Monitoring-system evidence-map structure
Figure 41. Communication-robot evidence-map structure
Figure 42. Trial-to-sustained-use conversion funnel
Figure 43. Unmet-need map: burden, turnover, mismatch
Figure 44. Evidence-generation program design framework
Figure 45. Facility business-case decision diagram
Figure 46. Operator adoption-archetype map
Figure 47. Export pathway map for Japanese care robotics
Figure 48. Policy lever map: subsidies, incentives, evidence rules
Figure 49. Methodology flow: vendor audit, subsidies, interviews
Figure 50. Data cut-off and update cadence schematic

Care Robotics: Vendors, Adoption, and Outcomes Evidence 2026 | Policy & Market Intelligence | US, EU5, Japan & China

Description

Table of Contents

List of Tables

Table of Content

1. Executive Summary

2. Care Robotics: Policy and Institutional Framework

3. Reimbursement, Pricing, and Funding Flows

4. Provider and Operator Landscape: Structure and Economics

5. Workforce and Capacity Analysis

6. Technology and Vendor Ecosystem

7. International Comparison: US, EU5, and China

8. Implications for Entrants and Investors

9. Appendix: Methodology and Sources

Companies Mentioned

List of Tables

List of Figures